Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
NTSK has climbed 38% over the past month and 10% this week, yet the market's short-sellers are not pressing the case against it. The interesting tension is between a stock that has run hard since IPO and a positioning setup that looks remarkably relaxed for a recent debut with a CFO transition, VC-heavy ownership, and ongoing losses.
The borrow market gives no signal of conviction on either side. Availability is at 589%, meaning there are roughly six shares available for every one already on loan. That is deep in the "plenty of supply" range and has actually loosened sharply from below 300% in early September, when short interest was also running higher. Shares short have fallen about 12% over the past month to roughly 12.6 million. Cost to borrow is 0.48%, low by any standard, up 18% on the week but well below where it stood through the summer. The ORTEX short score has drifted down from a peak near 49 in late September to 44 this week, reflecting the easing pressure across every borrow metric. Options positioning reinforces the theme: the put/call ratio is 0.24, nearly one-and-a-half standard deviations below its 20-day average of 0.30, close to its 52-week low of 0.18. Calls are dominating the flow. Overall, the setup looks bullish in tone rather than defensively positioned.
The Street has been moving in the same direction. After the September quarterly report triggered a broad round of target increases, BTIG this week raised its target from $18 to $22 while maintaining a Buy. That is now the most aggressive target on the board relative to a current price of $19.24. Most of the post-earnings upgrades, from JPMorgan, Morgan Stanley, RBC, Piper Sandler, Baird, BMO and Rosenblatt, landed targets in the $16 to $20 range, which the stock has since passed through. The mean price target of $19.08 is now effectively at spot. Stephens initiated at Overweight ($21) in mid-September, and Amerx initiated this week at Hold with no target, adding a cautious voice to an otherwise bullish chorus. The bull case rests on 27% ARR growth, $899 million of ARR, 114% to 115% net revenue retention, and a SASE market the company pegs at a $149 billion opportunity by 2028. Bears point to intensifying competition from larger platform vendors, CFO transition risk, volatile NNARR, and roughly 38% VC ownership that overhangs any further rally. On valuation, EV/EBITDA sits at 262x, a multiple that assumes substantial and sustained margin expansion from a business still running deep operating losses.
Retail attention is worth flagging. The ORTEX alt data layer shows Wikipedia pageview and ORTEX stock-page activity running at a z-score of 2.4 against NTSK's own 90-day history, a reading from late September. That is elevated retail attention by the company's own standards, consistent with a stock that has caught momentum traders' interest after a sharp move off the IPO price.
On ownership, the notable development this month is CEO Sanjay Beri adding 908,000 shares to reach a reported 6% stake as of October 1. That is a material open-market accumulation from the founder at a price near the current level. The VC register meanwhile shows dilution from the IPO period. Lightspeed and ICONIQ each hold around 13.8% and 13.75% respectively, unchanged in recent filings. BlackRock added roughly 5.9 million shares as of September 30, and Penserra Capital built a new position of 6.7 million shares over the same period, two passive and quasi-passive buyers absorbing supply. Most 13D/G filers have trimmed percentages as the share count expanded post-IPO. No 13D activist is on the register. All 13D/G positions are event-driven disclosures around the 5% threshold and are as last disclosed, holders falling below 5% may exit without further filing.
With earnings not due until December 3, the next 56 days are primarily about whether the stock can hold its gains above the analyst consensus target while VC overhang persists and the Street debates whether a 262x EV/EBITDA multiple on a loss-making SASE vendor is sustainable at these levels.
See the live data behind this article on ORTEX.
Open NTSK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
